Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001214659-26-006096
Filing Date
2026-05-13
Accepted
2026-05-13 16:15:10
Documents
1
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 13224
  Complete submission text file 0001214659-26-006096.txt   14948
Mailing Address 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Business Address 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121 858-200-3830
TANG CAPITAL MANAGEMENT LLC (Filed by) CIK: 0001232621 (see all company filings)

EIN.: 461592449 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Subject) CIK: 0001645666 (see all company filings)

EIN.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-90539 | Film No.: 26973452
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)